Research Topics
| E O ReiterSummaryAffiliation: Baystate Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
The KIGS experience with the addition of gonadotropin-releasing hormone agonists to growth hormone (GH) treatment of children with idiopathic GH deficiencyEdward O Reiter
Baystate Medical Center Children s Hospital, Tufts University School of Medicine Springfield, MA 01199, USA
Horm Res 60:68-73. 2003..These data suggest that the attainment of a substantial height SDS by manipulating the tempo of puberty is limited, but that optimizing growth during the pre-pubertal phase is a more important factor...- A brief review of the addition of gonadotropin-releasing hormone agonists (GnRH-Ag) to growth hormone (GH) treatment of children with idiopathic growth hormone deficiency: Previously published studies from AmericaEdward O Reiter
Baystate Children s Hospital, Tufts University School of Medicine, Springfield, MA 01199, USA
Mol Cell Endocrinol 254:221-5. 2006..No universally agreed guidelines exist for the use of GnRH-Ag plus GH in children with GHD or other short stature syndromes and may still be considered experimental... - Early initiation of growth hormone treatment allows age-appropriate estrogen use in Turner's syndromeE O Reiter
Departments of Pediatrics, Baystate Medical Center Children s Hospital and Tufts University School of Medicine, Springfield, Massachusetts 01199, USA
J Clin Endocrinol Metab 86:1936-41. 2001..If GH therapy were started early, E treatment could be initiated at a younger, more age-appropriate time without compromising adult height... - Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international databaseEdward O Reiter
Baystate Medical Center Children s Hospital, Tufts University School of Medicine, Springfield, Massachusetts 01199, USA
J Clin Endocrinol Metab 91:2047-54. 2006..Although successful in increasing height velocity, such treatment often falls short of helping patients achieve full genetic height potential... - Testotoxicosis: current viewpointEdward O Reiter
Department of Pediatrics, Baystate Children s Hospital, Tufts University School of Medicine, Springfield, MA 01199, USA
Pediatr Endocrinol Rev 3:77-86. 2005..These agents are well tolerated in the populations in which they have been studied and effectively inhibit testosterone activity and estrogen production, in adult patients... - Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT)Edward O Reiter
Baystate Children s Hospital, Tufts University School of Medicine, Springfield, MA, USA
J Pediatr Endocrinol Metab 23:999-1009. 2010..To evaluate the efficacy, tolerability, and pharmacokinetics of bicalutamide plus anastrozole in young males with testotoxicosis... - Educated?... For uncertaintyEdward O Reiter
Department of Pediatrics, Tufts University School of Medicine, Baystate Medical Center Children s Hospital, Springfield, MA 01199, USA
J Pediatr Endocrinol Metab 15:3-4. 2002 - A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiencyE O Reiter
Baystate Medical Center Children s Hospital, Tufts University School of Medicine, Springfield, MA 01199, USA
J Clin Endocrinol Metab 86:4700-6. 2001..Patients achieved similar growth velocities when sustained release GH was given once or twice monthly. The enhanced convenience of this dosage form may result in greater long-term adherence to the treatment regimen... - Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndromeHolley F Allen
Baystate Medical Center Children s Hospital, Tufts University School of Medicine, Springfield, MA 01199, USA
J Pediatr Endocrinol Metab 18:761-8. 2005..We evaluated the hypothesis that metformin would improve signs and symptoms of polycystic ovary syndrome (PCOS) in adolescents as compared to oral contraceptive pills (OCP) and have a favorable effect on obesity... - A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiencyBernard L Silverman
Department of Pediatrics, Northwestern University, Chicago, IL, USA
J Pediatr Endocrinol Metab 15:715-22. 2002..c.) injection. The availability of this formulation offers the opportunity for greater convenience and compliance by decreasing the number of injections and frequency of administration required... - Small for gestational age: short stature and beyondPaul Saenger
Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York 10467, USA
Endocr Rev 28:219-51. 2007..Recent data, however, suggest that long-term treatment with GH does not increase the risk of type 2 diabetes mellitus and the metabolic syndrome in young adults born SGA... - HIV--associated lipodystrophy in childrenJens C Krause
Baystate Children's Hospital, Tufts University School of Medicine, Department of Pediatrics, 759 Chestnut Street, Springfield, MA 01199, USA
Pediatr Endocrinol Rev 3:45-51. 2005..GH resistance in LD needs to be better characterized. While some cytokines show promise as markers for LD, it is difficult to tell whether their derangement is a cause of or the effect of LD... - Continuous glucose monitoring in children with type 1 diabetes: before and after insulin pump therapyRubina A Heptulla
Department of Pediatrics, Baylor College of Medicine, Texas Children s Hospital, Houston, TX 77030 2399, USA
Pediatr Diabetes 5:10-5. 2004..This study was undertaken to determine the specific areas of improved glycemic control in subjects after initiation of insulin pump therapy and times where further improvement is needed. Research.. - Delayed pubertyEdward O Reiter
Department of Pediatrics, Bayside Medical Center Children's Hospital, Tufts University School of Medicine, Sprinfield, Massachusetts 01199, USA
Adolesc Med 13:101-18, vii. 2002..Diagnostic assessment and varied therapeutic modalities are discussed. The issues of androgen or estrogen therapy are important to assess, and growth hormone treatment remains a difficult dilemma... - Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database)Maria E Craig
Institute of Endocrinology and Diabetes, Children s Hospital at Westmead, Westmead, NSW, Australia
Clin Endocrinol (Oxf) 65:178-85. 2006..To evaluate the response to recombinant GH treatment and adverse events in children with Prader-Willi syndrome (PWS) from KIGS, the Pfizer International Growth Database... - Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short statureMichael B Ranke
Paediatric Endocrinology Section, Children s Hospital, University of Tubingen, Tubingen, Germany
Horm Res 68:53-62. 2007..To develop methods to identify factors associated with a favorable outcome in GH-treated children with idiopathic short stature (ISS)... - Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trialErica A Eugster
Pediatric Endocrinology, Riley Hospital for Children, Indiana Uniuversity School of Medicine, 702 Barnhill Drive, Indianapolis, IN 46202, USA
J Clin Endocrinol Metab 92:1697-704. 2007..GnRH analog (GnRHa) therapy for central precocious puberty (CPP) typically involves im injections. The histrelin implant is a new treatment that provides a continuous slow release of the GnRHa histrelin... - Increased response, but lower responsiveness, to growth hormone (GH) in very young children (aged 0-3 years) with idiopathic GH Deficiency: analysis of data from KIGSMichael B Ranke
Pediatric Endocrinology Section, University Children s Hospital, Hoppe Seyler Strasse 1, D 72076 Tuebingen, Germany
J Clin Endocrinol Metab 90:1966-71. 2005..The early detection and GH treatment of congenital GHD is advantageous as a cost-effective strategy for achieving greater improvement of absolute height and growth velocity... - Final height in children with medulloblastoma treated with growth hormoneMichael B Ranke
Paediatric Endocrinology Section, Children s Hospital, University of Tubingen, Tubingen, Germany
Horm Res 64:28-34. 2005..Height in general is severely compromised in survivors. The present study is an extension of the investigation by the author's group of the effect of exogenous growth hormone (GH) among medulloblastoma patients... - Insulin-like growth factors as diagnostic tools in growth hormone deficiency during childhood and adolescence: the KIGS experienceMichael B Ranke
Paediatric Endocrinology Section, University Children s Hospital, Tubingen, Germany
Horm Res 62:17-25. 2004.... - Bone age progression during the first year of growth hormone therapy in pre-pubertal children with idiopathic growth hormone deficiency, Turner syndrome or idiopathic short stature, and in short children born small for gestational age: analysis of data frFeyza Darendeliler
Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Horm Res 63:40-7. 2005.... - Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database)Michael B Ranke
Sektion Pädiatrische Endokrinologie, Universitatsklinikum Tubingen, Eberhard Karls Universitat, D 72076 Tubingen, Germany
J Clin Endocrinol Metab 88:125-31. 2003..Furthermore, this model can be used to provide patients with a realistic expectation of treatment and may help to identify compliance problems or other underlying causes of treatment failure... - The mathematical model for total pubertal growth in idiopathic growth hormone (GH) deficiency suggests a moderate role of GH doseMichael B Ranke
Pediatric Endocrinology Section, University Children s Hospital, Tubingen D 72076 Germany
J Clin Endocrinol Metab 88:4748-53. 2003..The use of a higher GH dosage at the onset of puberty should thus depend on the individual's height development. The TPG model aids in the planning of individually optimized and cost-effective GH treatment... - Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trialErica A Eugster
James Whitcomb Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
J Pediatr 143:60-6. 2003..We undertook a 1-year multicenter trial of tamoxifen treatment for precocious puberty in girls with McCune-Albright syndrome (MAS)... - Work group I: developing models of healthy adolescent physical developmentElizabeth J Susman
The Pennsylvania State University, University Park, Pennsylvania 16802, USA
J Adolesc Health 31:171-4. 2002 - Major determinants of height development in Turner syndrome (TS) patients treated with GH: analysis of 987 patients from KIGSMichael B Ranke
Paediatric Endocrinology Section, Children s Hospital, University of Tuebingen, D 72076 Tuebingen, Germany
Pediatr Res 61:105-10. 2007..Evidently, height at GH start (the taller, the better), age at GH start (the younger, the better), the responsiveness to GH (the higher, the better) and age at puberty (the later, the better) determine NAH... - Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trialPaul V Plourde
AstraZeneca Pharmaceuticals LP, Chesapeake 2B 126, 1800 Concord Pike, P O Box 15437, Wilmington, Delaware 19850 5437, USA
J Clin Endocrinol Metab 89:4428-33. 2004.... - A growth prediction model for short children born small for gestational ageMichael B Ranke
Paediatric Endocrinology Section, University Children's Hospital, , Germany
J Pediatr Endocrinol Metab 15:1273. 2002